Muscle Injury |
Peter C Belafsky |
University of California, Davis |
Phase 1/2 |
Recruiting |
62 |
|
Immune Disease |
DR Jonathan Benjamin |
ImmPACT-Bio, Inc. |
Phase 1/2 |
Launching |
N/A |
|
Cystinosis Kidney Failure |
Dr. Stephanie Cherqui |
University of California, San Diego |
Phase 1/2 |
Active, not recruiting |
6 |
|
HIV/AIDS Immune Disease |
Steven G. Deeks |
University of California, San Francisco |
Phase 1/2 |
Recruiting |
18 |
|
Developmental Disorders Spina Bifida |
Dr. Diana L. Farmer |
University of California, Davis |
Phase 2 |
Recruiting |
55 |
|
Immune Disease Severe Combined Immunodeficiency, X-linked (X-SCID) |
Stephen Gottschalk |
St. Jude Children’s Research Hospital |
Phase 1/2 |
Suspended |
28 |
|
Bone or Cartilage Disease Hearing Loss Intellectual Disability Metabolic Disorders Vision Loss |
Dr Robert Hayes |
Immusoft Corporation |
Phase 1 |
Launching |
N/A |
|
Arthritis Osteoarthritis |
Dr. Kristen A Johnson |
Calibr |
Phase 1 |
Completed |
60 |
|
Neurological Disorders Other |
Prof. Olivia Kim-McManus |
University of California, San Diego |
Phase 1/2 |
Launching |
N/A |
|
Immune Disease Pediatrics X-linked Chronic Granulomatous Disease |
Dr. Donald B. Kohn PhD |
University of California, Los Angeles |
Phase 1/2 |
Recruiting |
16 |
|
Pediatrics Sickle Cell Disease |
Dr. Donald B. Kohn PhD |
University of California, Los Angeles |
Phase 1 |
Active, not recruiting |
4 |
|
Genetic Disorder Immune Disease Pediatrics Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) |
Dr. Donald B Kohn Leslie Meltzer Dr. Donald B. Kohn PhD |
University of California, Los Angeles Orchard Therapeutics plc |
Phase 2 |
Completed |
10 |
|
Pulmonary Hypertension Vascular Disease |
Dr. Michael I Lewis |
Cedars-Sinai Medical Center |
Phase 1/2 |
Completed |
26 |
|
Immune Disease Pediatrics Severe Combined Immunodeficiency, X-linked (X-SCID) |
Dr. Judith A Shizuru Wendy Pang |
Stanford University Jasper Therapeutics, Inc. |
Phase 1/2 |
Recruiting |
40 |
|
Immune Disease Leukocyte Adhesion Deficiency |
Dr. Kinnari Patel |
Rocket Pharmaceuticals, Inc. |
Phase 1/2 |
Completed |
9 |
|
Danon Disease Pediatrics |
Dr. Jonathan Schwartz |
Rocket Pharmaceuticals, Inc. |
Phase 2 |
Launching |
N/A |
|
Solid Tumors |
Dr. Dennis J Slamon |
University of California, Los Angeles |
Phase 1 |
Completed |
46 |
|
Lupus, Systemic Lupus Erythematosus (SLE) |
Bob Valamehr |
Fate Therapeutics, Inc. |
Phase 1 |
Launching |
N/A |
|
COVID-19 Respiratory Disorders |
William van der Touw |
Celularity Inc. |
Phase 1/2 |
Unknown status |
86 |
|
Blood Cancer Solid Tumors |
Professor Irving L Weissman MD |
Stanford University |
Phase 1 |
Completed |
88 |
|
Bladder or Urinary Tract Disorder |
James Yoo |
Wake Forest University Health Sciences |
Phase 1 |
Not yet recruiting |
10 |
|
COVID-19 Respiratory Disorders |
Prof. John A. Zaia |
City of Hope, Beckman Research Institute |
Phase 1 |
Launching |
N/A |
|